Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of ADAR1 Expression Level on Total Neoadjuvant Treatment Response in Locally Advanced Rectal Cancer

NCT07108348 is registered in ClinicalTrials.gov with Necmettin Erbakan University as lead sponsor.

NCT NCT07108348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of ADAR1 Expression Level on Total Neoadjuvant Treatment Response in Locally Advanced Rectal Cancer
Lead sponsor
Necmettin Erbakan University
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2025
Completion date
September 1, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectum cancer, adenocarcinoma